Compare RBBN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | DCTH |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | 3080 | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.8M | 372.5M |
| IPO Year | 2017 | 2015 |
| Metric | RBBN | DCTH |
|---|---|---|
| Price | $2.01 | $12.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.67 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 784.5K | 379.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | 107.53 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.97 | $24.54 |
| Revenue Next Year | $6.69 | $33.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $8.12 |
| 52 Week High | $4.24 | $13.74 |
| Indicator | RBBN | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 44.31 |
| Support Level | $1.83 | $9.98 |
| Resistance Level | $2.86 | $12.48 |
| Average True Range (ATR) | 0.14 | 0.51 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 5.49 | 1.71 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.